NasdaqGM - Delayed Quote • USD
Arcturus Therapeutics Holdings Inc. (ARCT)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 9 |
| Avg. Estimate | -1.19 | -1 | -2.51 | 0.22 |
| Low Estimate | -1.71 | -1.78 | -5.97 | -5.11 |
| High Estimate | -0.84 | 0.22 | -0.37 | 9.92 |
| Year Ago EPS | 1.87 | -1.98 | -1 | -2.51 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 9 |
| Avg. Estimate | 17.54M | 23.8M | 146.3M | 250.59M |
| Low Estimate | 6M | 6M | 55.51M | 111.72M |
| High Estimate | 29.34M | 73.36M | 293.45M | 771.01M |
| Year Ago Sales | 79.73M | 10.52M | 169.93M | 146.3M |
| Sales Growth (year/est) | -78.00% | 126.30% | -13.90% | 71.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.06 | -0.21 | -1.69 | -0.99 |
| EPS Actual | 1.87 | -1.98 | -0.61 | -0.32 |
| Difference | 1.81 | -1.77 | 1.08 | 0.67 |
| Surprise % | 3,016.70% | -842.90% | 63.90% | 67.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.19 | -1 | -2.51 | 0.22 |
| 7 Days Ago | -1.05 | -0.89 | -2.35 | 0.6 |
| 30 Days Ago | -1.05 | -0.89 | -2.35 | 0.6 |
| 60 Days Ago | -1.06 | -1.02 | -3.29 | 2.87 |
| 90 Days Ago | -1.06 | -1.02 | -3.29 | 1.81 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | ARCT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -163.60% | -- | -- | 2.60% |
| Next Qtr. | 49.50% | -- | -- | 13.40% |
| Current Year | -151.00% | -- | -- | 5.20% |
| Next Year | 108.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/20/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 3/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/8/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/8/2024 |
| Maintains | Citigroup: Buy to Buy | 2/8/2024 |
| Initiated | Canaccord Genuity: Buy | 12/13/2023 |
Related Tickers
CVAC CureVac N.V.
2.3100
-7.97%
RNA Avidity Biosciences, Inc.
23.83
-5.02%
DTIL Precision BioSciences, Inc.
9.72
-1.02%
ZYME Zymeworks Inc.
8.11
-5.15%
EDIT Editas Medicine, Inc.
5.22
-2.43%
CGEM Cullinan Therapeutics, Inc.
19.25
+1.91%
AXSM Axsome Therapeutics, Inc.
71.52
+0.49%
RGNX REGENXBIO Inc.
16.06
+0.12%
RARE Ultragenyx Pharmaceutical Inc.
43.85
-0.97%
BEAM Beam Therapeutics Inc.
21.60
-5.01%